Nutrition-Related Biomarkers in Predicting Breast Cancer Risk in Women
Recruitment status was Active, not recruiting
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about nutrition-related changes that identify biomarkers related to cancer. It may also help doctors predict a woman's risk of developing breast cancer.
PURPOSE: This laboratory study is looking at nutrition-related biomarkers in predicting breast cancer risk in women.
Other: high performance liquid chromatography
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Cohort|
|Official Title:||Nutrition Modulated Metabolism as a Disease Risk Factor|
- Generation of metabolome profiles that reflect nutritional status [ Time Frame: ongoing ] [ Designated as safety issue: No ]
- Utility of rat metabolome profiles for human epidemiological studies [ Time Frame: ongoing ] [ Designated as safety issue: No ]
- Utility of metabolome profiles in predicting relative risk of developing breast cancer [ Time Frame: ongoing ] [ Designated as safety issue: No ]
- Identification of critical serum metabolites [ Time Frame: ongoing ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
we have only plasma, NHS has DNA samples.
Study is nested case control, so retrospective with respect to individual inclusion, prospective with respect to sample collected before disease. Enrollment is approximate as it includes samples that will be drpped, eg for QC resons
|Study Start Date:||July 2005|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
- To complete characterization of metabolic serotypes based on the metabolome, and to adapt these profiles for human epidemiological studies.
- To determine the extent to which metabolic profiles that are reflective of or independent of long-term caloric intake predict breast cancer risk in nested case-control studies.
- To identify critical serum metabolites.
OUTLINE: Laboratory studies, including metabolome profiling by high performance liquid chromatography; and small molecule identification by mass spectroscopy, are performed on previously collected blood samples.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00900367
|United States, Massachusetts|
|Dana-Farber/Brigham and Women's Cancer Center|
|Boston, Massachusetts, United States, 02115|
|Study Chair:||Bruce S. Kristal, PhD||Brigham and Women's Hospital|